Dosing chart / Growth hormone
Sermorelin vs Tesamorelin
Dose, schedule, route and approval status side by side.
Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.
| Sermorelin | Tesamorelin | |
|---|---|---|
| Status | Not approved | FDA-approved |
| Also known as | Geref | Egrifta SV, Egrifta WR |
| Typical dose | 200–500 mcg | 1.4 mg (SV) or 1.28 mg (WR) |
| How often | Daily, at bedtime | Daily |
| Schedule | Once daily at bedtime. | Once daily into the abdomen. |
| Daily equivalent | 200–500 mcg/day | 1.28–1.4 mg/day |
| Route | Subcutaneous | Subcutaneous |
| Duration | 3–6 months reported | Ongoing |
| Notes | Formerly FDA-approved for childhood growth hormone deficiency; the brand was discontinued commercially. Now available only through compounding. | Approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. The original formulation was 2 mg daily. The two current formulations are not interchangeable. Calculator values assume a compounded vial. |
This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the Sermorelin and Tesamorelin pages.
Advertisement